Dougherty & Co initiated coverage on shares of ENDRA Life Sciences (NASDAQ:NDRA) in a research report released on Thursday morning, The Fly reports. The brokerage issued a buy rating on the stock.
Separately, Lake Street Capital started coverage on shares of ENDRA Life Sciences in a research note on Monday, May 20th. They set a buy rating for the company.
Shares of NASDAQ NDRA opened at $1.65 on Thursday. ENDRA Life Sciences has a 52-week low of $0.90 and a 52-week high of $5.75.
Several large investors have recently bought and sold shares of NDRA. Geode Capital Management LLC acquired a new position in shares of ENDRA Life Sciences during the 4th quarter valued at $71,000. Creative Planning acquired a new position in shares of ENDRA Life Sciences during the 4th quarter valued at $53,000. National Asset Management Inc. acquired a new position in ENDRA Life Sciences in the 4th quarter worth $35,000. Finally, Virtu Financial LLC lifted its holdings in ENDRA Life Sciences by 109.2% in the 1st quarter. Virtu Financial LLC now owns 28,602 shares of the company’s stock worth $47,000 after buying an additional 14,930 shares in the last quarter. Institutional investors and hedge funds own 17.17% of the company’s stock.
About ENDRA Life Sciences
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.